Hussein A. Tawbi, MD, PhD
Articles
Expert Talks Significance of Relatlimab/Nivolumab Approval for Metastatic Melanoma
March 30, 2022
Video
Hussein A. Tawbi, MD, PhD, principal investigator of the phase 2/3 RELATIVITY-046 trial, highlights the importance of relatlimab/nivolumab’s recent FDA approval in melanoma.
Expert Explains Significance of LAG-3 Inhibition in Novel Immunotherapies for Melanoma
January 28, 2022
Video
LAG-3 represents a potentially relevant immune checkpoint pathway in melanoma treatment.
Expert Explains Rationale Behind RELATIVITY-047 in Melanoma
January 19, 2022
Video
Dr. Hussein Tawbi, MD, PhD, explains the rationale behind the RELATIVITY-047 trial in melanoma and how the LAG-3 findings could further revolutionize immunotherapy.
Advertisement
Advertisement